Metabolite Profiling of Extract and Fractions of Bidara Upas (Merremia Mammosa (Lour.) Hallier F.) Tuber Using UPLCQToF-MS/MS

Abstract

Bidara upas (Merremia mammosa (Lour.) Hallier f.) tuber is empirically used to treat respiratory disorders and tuberculosis. The pharmacological effect is due to the activity of various secondary metabolites. This study aims to determine the metabolite profile of M. mammosa tuber ethanol extract, n-hexane fraction, ethyl acetate fraction, and n-butanol fraction. The dried powder of the tuber of M. mammosa was extracted with 96% ethanol. Then, liquid-liquid fractionation was performed using n-hexane, ethyl acetate, and butanol as solvents. As much as 5 µl of each sample was injected into the UPLC-QToF-MS/MS and analyzed using the MassLynx 4.1 software and the ChemSpider and MassBank online databases. After identifying each compound, information regarding its activity was retrieved from the scientific literature. Metabolite profiling revealed that the 96% ethanol extract of M. mammosa yielded 61 compounds, with the n-hexane fraction yielding 64 compounds, the ethyl acetate fraction yielding 54 compounds, and the butanol fraction yielding 44 compounds. According to the findings of this study, the metabolite profiles of each M. mammosa tuber extract and fractions were distinct. Several compounds in these extracts and fractions may have antiviral, antioxidant, anti-inflammatory, and other properties; hence, more studies are required to determine their potential.

Untitled

“…The cytotoxic test with Vero E6 cells (host of the SARS-CoV2 virus) from the ethanol extract of bidara upas using the MTT method showed that the maximum non-toxic concentration (MNTC) is 500 µg/mL, as determined as the maximum concentration of the extract at which the cells developed normally, therefore the viral inhibition assay used 500 µg/mL as highest concentration [18,19]. The concentration that determined a cell viability above 80% [20]. However, in this research, the viability of cell is 41%.…”

The activity of bioactive compounds from bidara upas (Merremia mammosa (Lour) Hall. f.) as an inhibitor of SARS-CoV2 entry stage: In silico study

“…Using Agilent LC-MS/MS QTOF, a total of 206 compounds were predicted from 96% of its ethanol extract, butanol fraction, ethyl acetate fraction, and nhexane fraction (Purwitasari, 2022). Through metabolite profiling were then subjected to a molecular docking study to predict the potential compounds that can inhibit the TMPRSS2 of SARS-CoV-2.…”

Inhibition of Spike Protein of SARS-CoV2 from (Merremia mammosa (Lour) Hall. F.) Bioactive Compounds: Molecular Docking and ADMET Study

“…The objective of this research was to investigate the interaction between the spike protein of SARS-CoV2 and Merremia mammosa (Lour) through the process of docking. Previously, our investigation using LC-MS/MS QTOF equipment, discovered a total of 206 compounds in four different fractions (96% ethanol extract, butanol, ethyl acetate, and n-hexane) obtained from Merremia mammosa (Lour) (Purwitasari & Agil, 2022).…”